AstraZeneca Korea announced on the 4th that it has appointed Lim Jae-yoon (Country Medical Director) to oversee the medical department.
Lim Jae-yoon, Executive Director of the Medical Department of AstraZeneca Korea, joined the Medical Department of AstraZeneca Korea as Oncology therapeutic area Leader in 2019 and contributed to the confirmation of AstraZeneca’s scientific leadership in the process of clinical trials, launch, reimbursement, and partnerships of anti-cancer products. cancer did.
In particular, in the process of rapidly expanding the anticancer drug portfolio, he has proven his leadership within the organization in the process of launching major anticancer drug products such as Tagrisso, Impinzi, Enhertu, Lynparza, and Cocellugo, expanding the signs, and provide reimbursement. .
Before joining AstraZeneca Korea, Lim led the clinical development of anticancer drugs at Samsung Bioepis. Prior to that, he served as a postdoctoral researcher at the MD Anderson Cancer Center Research Institute at the University of Texas, USA, and as a professor at Yonsei University College of Medicine for approx. 8 years of accumulated experience in
Executive Director Lim obtained a medical oncology specialist from Yonsei University College of Medicine and has been active in domestic and international academic activities as a regular member of the Korean Cancer Society, the American Society of Oncology (ASCO), and the European Society of Oncology. ESMO).
